Patents by Inventor Shelly Ann Glase

Shelly Ann Glase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted morpholine compounds for the treatment of central nervous system disorders
    Patent number: 7659394
    Abstract: This invention relates to compounds of the formulae I wherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: February 9, 2010
    Assignee: Pfizer Inc
    Inventors: Nancy S. Barta, Shelly Ann Glase, David L. Gray, Gregory A. Reichard, Lloyd Jerome Simons, Wenijan Xu
  • Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
    Patent number: 6972287
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well as new compounds of Formula (I).
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: December 6, 2005
    Assignee: Pfizer Inc.
    Inventors: Corinne Elizabeth Augelli-Szafran, Mark Robert Barvian, Christopher Franklin Bigge, Shelly Ann Glase, Shunichiro Hachiya, John Steven Kiely, Takenori Kimura, Yingjie Lai, Annette Theresa Sakkab, Mark James Suto, Larry Craswell Walker, Tomoyuki Yasunaga, Nian Zhuang
  • Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
    Publication number: 20040220235
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula I 1
    Type: Application
    Filed: June 2, 2004
    Publication date: November 4, 2004
    Inventors: Corinne Elizabeth Augelli-Szafran, Mark Robert Barvian, Christopher Franklin Bigge, Shelly Ann Glase, Shunichiro Hachiya, John Steven Kiely, Takenori Kimura, Yingjie Lai, Annette Theresa Sakkab, Mark James Suto, Lary Craswell Walker, Tomoyuki Yasunaga, Nian Zhuang
  • Method of imaging amyloid deposits using substituted rhodanine derivatives
    Publication number: 20040197268
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula I 1
    Type: Application
    Filed: April 21, 2004
    Publication date: October 7, 2004
    Inventors: Corinne Elizabeth Augelli-Szafran, Shelly Ann Glase, Terri Stoeber Purchase
  • 2-phenyl benzimidazole derivatives as MCP-1 antagonists
    Patent number: 6534521
    Abstract: The present invention relates to novel compounds and medical methods of treatment of inflammation, atherosclerosis, restenosis, and immune disorders especially those associated with lymphocyte or monocyte accumulation such as arthritis and transplant rejection. More particularly, the present invention concerns the use of 2-phenyl benzimidazole derivatives.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 18, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
  • 2-phenyl benzimidazole derivatives as MCP-1 antagonists
    Publication number: 20020099054
    Abstract: Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1
    Type: Application
    Filed: October 25, 2001
    Publication date: July 25, 2002
    Applicant: Warner-Lambert Company
    Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
  • 2-phenyl benzimidazole derivatives as MCP-1 antagonists
    Patent number: 6348487
    Abstract: Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders wherein A is N or CH; where W, X, Y, and Z can be independently C—R2, C—R3, C—R4, C—R5, or N; no more than two of W, X, Y, and Z can be N in any one structure, R2, R3, R4, and R5 are as define in the specification.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: February 19, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
  • 2-phenyl benzimidazole derivatives as MCP-1 antagonists
    Patent number: 6184235
    Abstract: The present invention relates to novel compounds and medical methods of treatment of inflammation, atherosclerosis, restenosis, and immune disorders especially those associated with lymphocyte or monocyte accumulation such as arthritis and transplant rejection. More particularly, the present invention concerns the use of 2-phenyl benzimidazole derivatives.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: February 6, 2001
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
  • Tetrahydroquinoxaline dopamine D4 receptor antagonists
    Patent number: 5885994
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors having Formula I below ##STR1## This invention also relates to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: March 23, 1999
    Assignee: Warner-Lambert Company
    Inventors: Shelly Ann Glase, Suzanne Ross Kesten